Which biotech company does Vertex admire? Hint: It’s one some analysts think the CF drugmaker should bought a long time ago.

With its latest FDA nod, Bristol-Myers Squibb’s Opdivo won the right to take on Bayer's Stivaga in liver cancer.

Steve Miller, CMO of Express Scripts, is not mincing words in his assessment of Kymriah, Novartis' $475,000 CAR-T treatment for leukemia.

Intercept has been the presumed leader in the NASH drug race, but 19 deaths in current Ocaliva patients pose a threat to those plans.

The breast cancer med Ibrance has been a shooting star in Pfizer’s universe, and it’s expected to burn brightly enough to lift the whole company.

AbbVie and Roche amped up blockbuster hopes for Venclexta, their blood cancer drug, with data pointing the way to a big new approval.

Keytruda's stumble in multiple myeloma has prompted the FDA to halt recruitment in Roche's Tecentriq tests in that cancer.

Sanofi, Regeneron and Amgen, locked in a PCSK9 market battle, are touting the cholesterol drugs' benefits for patients with diabetes.

Samsung Bioepis has taken a big step toward approval for a Herceptin biosim in Europe.

Tesaro is in strong position to win another regulatory victory for its drug Zejula, which could boost its standing in the market for PARP inhibitors to treat…